

The Practical

Peer-Reviewed

Journal

For

Primary Care

Physicians

Postgraduate Medicine Online

[about us](#) | [cme](#) | [home](#) | [issue index](#) | [patient notes](#) | [pearls](#) | [ad services](#)

Systemic lupus erythematosus

Measures to keep this unpredictable disease under control

Brent Greenberg, MD; Margaret Michalska, MD

VOL 106 / NO 6 / NOVEMBER 1999 /
POSTGRADUATE MEDICINE

CME learning objectives

- To recognize common signs and symptoms of SLE
- To become familiar with criteria established by the American College of Rheumatology as the basis for diagnosis
- To identify appropriate treatment and preventive measures

<input type="checkbox"/> Search
<input checked="" type="checkbox"/> Match All
<input type="checkbox"/> Focus On
<input type="checkbox"/> CAD
<input type="checkbox"/> Diabetes
<input type="checkbox"/> Geriatrics
<input type="checkbox"/> Hypertension
<input type="checkbox"/> Rheumatology
<input type="checkbox"/> Women's Health
<input type="checkbox"/> Current Issue
<input type="checkbox"/> Web Exclusives
<input type="checkbox"/> Subscriptions
<input type="checkbox"/> Info for Authors
<input type="checkbox"/> Registration
<input type="checkbox"/> Medical Books

This page is best viewed with a browser that supports tables.

Preview: Systemic lupus erythematosus (SLE) is frustrating to the medical community and patients alike. The cause of this autoimmune disease is unknown, and nearly all of its clinical features are seen in other diseases as well. Further, the classic malar rash specific to SLE occurs in less than half of SLE patients, and diagnostic tests touted over the past half century have shown crossover with other autoimmune diseases (1). However, certain accepted criteria for diagnosis, and the therapeutic measures that can prolong survival and decrease mortality, have been developed to keep this unpredictable disease under control. *Postgrad Med* 1999;106(6):23-23

but this finding may be influenced by socioeconomic factors (2).

A familial correlation exists, especially in first-degree relatives. Cross-reacting autoantibodies such as rheumatoid arthritis and idiopathic thrombocytopenic purpura may be seen in other family members. (check SLE) may be distinguished from the systemic form.

Despite hereditary influence, most cases of SLE are idiopathic (2). Environmental factors may play a role, as suggested by a study showing that dogs belonging to patients with a new diagnosis of SLE had a higher frequency of anti-DNA antibodies than dogs belonging to subjects in the general population (3).

What causes SLE

Lupus is a chronic inflammatory disease of unknown origin. It is characterized by the body's production of antibodies to nuclear components of the cell. Whether it is a single condition or a group of related diseases is not known. The cutaneous form of SLE that is confined to the integument (check SLE) may be distinguished from the systemic form.

Pathogenesis is likely multifactorial. Genetically predispositioned immunologic influences, such as associations with HLA class II alleles (DR2 and DR3), play a role along with complement deficiencies (primarily C4d and C1q) and ethnic susceptibilities (4). Heterozygous C4d deficiency is associated with a high risk for SLE. This deficiency has been postulated to increase the risk for impaired clearance of foreign antigen, and this could potentially stimulate the immune system, leading to a chronic inflammatory response.

Viral and bacterial antigens have long been thought to be a possible source of SLE, but no pathogen has been consistently determined. Certain medications and environmental exposures have been found to create or exacerbate SLE symptoms.

Prognosis

Forty years ago, most people with SLE survived less than 5 years. Changes in diagnosis and treatment have improved survival to the point where more than 50% of patients now survive for more than 10 years (5). Most live a relatively asymptomatic life.

The most common cause of death is infection resulting from the immunosuppressive side effects of medications used to treat the disease. Renal and neuropsychiatric manifestations cause the greatest mortality and are associated with worse prognosis than other manifestations (1). Overall, prognosis is usually worse in men and children than in women. Life-threatening complications are most common in the first 5 years of manifestations. Symptoms that begin after age 60 tend to run a more benign course.

Symptoms and signs of SLE

In 1895, Sir William Osler described SLE in this manner (6):

By exudative erythema is understood a disease of unknown etiology with polymorphous skin lesions—hyperemia, edema, and more or less hemorrhage, of which the most important are gustic, intestinal crises, endocarditis, pericarditis, acute nephritis, and peritonitis from the mucous surfaces. Recurrence is a special feature . . . and attacks may come on month after month or even throughout a long period of years.

Osler's observations, compiled without the benefit of powerful laboratory tools, still provide an accurate picture of SLE, as discussed in the following sections.

Constitutional signs and symptoms

Common initial and chronic complaints are fever, malaise, myalgias, and weight loss. Because they are so often seen with other diseases, these signs and symptoms are not part of the diagnostic criteria for SLE. However, when they occur in conjunction with other signs and symptoms, they should be considered suggestive. Fatigue is often a chronic and unrelenting condition in SLE, but worsening fatigue may reflect a lupus flare.

Musculoskeletal conditions

Arthralgia is the most common reason patients with SLE seek medical attention. Small joints of the hand and wrist, usually are affected, often in a migratory presentation, but any joint is at risk. Soft-tissue and tendon thickening causes swelling that involves little of the joint; therefore, effusions, if any, are small.

Unlike rheumatoid arthritis, SLE arthropathy is usually not erosive or destructive to bone. Patients may complain of morning stiffness, but with few physical findings; however, deformities may become irreversible. According to arthropathy, with deformant ligamentous laxity, subluxations, and tendon ruptures, may develop in as many as 20% (7).

Dermatologic manifestations

Skin manifestations are second only to arthralgias in frequency. As many as 20% of patients present with dermatologic symptoms (and 55% manifest such symptoms at some point) secondary to destruction of the skin by deposition of immune complexes in the dermal-epidermal junction (8). In 30% to 50% of patients, malar rash develops after sunlight exposure. This may be a pruritic and painful erythematous flat patch or raised plaque over malar eminences, sparing nasolabial folds.

Subacute cutaneous lupus erythematosus

Subacute cutaneous lupus erythematosus is a distinct, nonscarring, coin-shaped lesion that occurs over sun-exposed areas and mimics psoriasis. Patients often demonstrate the antiSS-A (Ro) antibody (3).

Vasculopathy

Arterial and venous thrombosis is a sequel to chronic inflammatory events triggered by autoantibodies. Anticardiolipin and lupus anticoagulant antibodies are the most common serologic findings, but their mechanisms are unknown. Vasculitis can occur in the form of petechiae, purpura, or ecchymoses in the skin or swollen medium-sized vessels causing tender nodules. Seizures, strokes, or behavioral changes may ensue if the cerebral vessels are affected. Renal and coronary arteries are rarely involved (3).

Renal involvement

Because of early recognition and aggressive management of SLE, renal symptoms are rarely a problem until advanced nephrotic syndrome or renal failure develops. Patients hematuria or proteinuria may be the only presenting symptom. Renal disease develops in about 35% of patients, but end-stage renal failure occurs in less than 5% (3).

Cardiac symptoms

Pericarditis, myocarditis, and endocarditis can occur from nonspecific inflammation. Libman-Sacks or verrucous lesions are rare since corticosteroids became available for treatment. However, these lesions can manifest as immune complexes on the mitral valve, where bacteria can accumulate. Lesions, even when clinically silent, are found in more than half of autopsies. Atherosclerosis tends to occur more often (9:1 ratio) and to advance more rapidly in patients with SLE than in the general population.

Thus, these patients are at increased risk for myocardial infarction (9).

Serologic features

Pluritis, pericarditis, and peritonitis are common features of SLE. Pleural effusions are usually small but can be large. The fluid often contains antinuclear antibodies (ANAs), low complement, and immune complexes. Leukopenia may be due to SLE or to side effects of pharmacologic treatment.

Hematologic manifestations

Anemia secondary to chronic inflammation, iron deficiency, and hemolysis may develop in as many as half of SLE patients. Thrombocytopenia and leukopenia may be due to SLE or to side effects of pharmacologic treatment. About 10% of patients with SLE may have a neuropsychiatric manifestation as the presenting symptom. A third may have positive findings on examination of cerebrospinal fluid. Magnetic resonance imaging may show focal areas of increased signal intensity. Electroencephalography and gallium scans have not shown any diagnostic value. Computed tomography may be useful for viewing infarcts (9).

Diagnosis of SLE

In 1982, the American College of Rheumatology revised their criteria for diagnosis of SLE (Table 1; not shown). Four of their 11 criteria must be met, either together or at different times. These criteria are widely accepted for use in clinical trials and to guide therapy.

Laboratory tests

The American College of Rheumatology has delineated criteria for the diagnosis of SLE. Various laboratory tests, when considered in conjunction with clinical findings, point to the diagnosis.

Diagnostic criteria

In 1982, the American College of Rheumatology revised their criteria for diagnosis of SLE (Table 1; not shown). Four of their 11 criteria must be met, either together or at different times. These criteria are widely accepted for use in clinical trials and to guide therapy.

Today, the ANA test is the mainstay in diagnosis of SLE. This test has high sensitivity but poor specificity. A test using fixed and permeabilized human HEp-2 cells measures binding of the patient's serum antibodies to the cell nuclei (10). Antibodies against the nucleolus are seen in more than 90% of patients at some time. The false-positive rate is 3% overall but increases with age. High titers are seen in 95% of active flares and in drug-induced flares. Over 50% of titers during flares exceed 1:50 dilutions (10).

The immunofluorescent patterns of antibody distribution correlate with certain autoimmune disease states. Nucleolar, nonnucleolar, and speckled patterns are seen in various diseases, including SLE. However, one peripheral pattern is the most specific to SLE, although less commonly seen (11). Subtypes of nuclear patterns have been found to overlap with other rheumatologic diseases, but antibodies to double-stranded DNA (anti-dsDNA) and to an RNA protein complex (anti-Sm) have been found to be most diagnostic of SLE.

When autoimmune flares occur, complement factors are consumed. Low complement levels, particularly C3 and C4, have also been used as important measures. Among SLE patients, 11% have an inherited complement defect (9). Although ANA titer, serum patterns, and complement levels are useful in diagnosis, they are most consistent in following flares. These levels may rise a few or more days before clinical disease flares. Anti-dsDNA may be seen 30% to 50% of the time, while an anti-Sm may be seen 7% to 10% of the time (2). Immunologic markers can be useful but should not substitute for assessment or clinical manifestations when guiding a treatment plan.

Urinalysis demonstrating hematuria (>5 red blood cells per high-power field), presence of any casts, pyuria (>5 white blood cells per high-power

finds) in the absence of infection, and proteinuria (>0.5 g/dL or $3+$ protein on dipstick) may indicate renal involvement. In the context of other clinical signs, these findings warrant a renal work-up.

Leukocytes, primarily polymorphonuclear neutrophils, are often decreased during a flare. This occurs because leukocytes bind to complement receptors, creating a cascade of proteolytic enzymes that perpetuate inflammation and adhere to vascular endothelium, possibly leading to the occlusion of small blood vessels. Autoantibodies bind to platelets, causing thrombocytopenia that sometimes manifests as ecchymosis or bleeding from the gums, nose, or gastrointestinal tract. Unlike in idiopathic thrombocytopenic purpura, splenectomy is rarely necessary.

Cerebrospinal fluid findings emulate those of aseptic meningitis. Increased protein levels and pleocytosis are found in 50% of patients.

A false-positive latex plasma reagent test may occur in conjunction with a negative fluorescent strip antigen absorption test. These findings often correlate with a positive lupus anticoagulant or antiphospholipid antibody test.

In small-joint effusions, a high percentage of polymorphonuclear neutrophils without a concomitant infection or decreased complement levels is often seen.

The erythrocyte sedimentation rate can be high, but this occurs too inconsistently to be useful in diagnosing SLE or monitoring flare progression.

Special cases of SLE

Because of the complexity of SLE, some special cases must be noted that have a different pathogenesis and course.

Pregnancy in SLE patients

Fertility rates in women with SLE match those in the general population. However, half the pregnancies in these women result in premature birth or spontaneous abortion, most often during the second trimester. Constitutional symptoms and rash are the most common problems, occurring most often early in the pregnancy. Many patients manifest symptoms that may be indistinguishable from preeclampsia (7,12).

Prednisone, nonsteroidal antiinflammatory drugs (NSAIDs), and most other medications for treating lupus symptoms are safe to use in pregnancy. Hydroxychloroquine (Plaquenil) sulfate and azathioprine (Imuran) are under investigation for their safety. Cyclophosphamide (Cytoxan, Neosar) and methotrexate (Rheumatrex, Folex, Rheumatrex) are contraindicated in pregnancy.

Neonatal lupus

A third of mothers with antiSSA (Ro) antibody, 10% of these will give birth to a baby with neonatal lupus. The most common symptoms are rash, transient anemia and rarely, complete heart block. Except for the cardiac manifestations, the illness is typically transient and resolves by age of 1 to 2 months (2).

Drug-induced lupus

In 1945, the first lupuslike reaction to a medication was reported with sulfasalazine (Azulfidine), causing or exacerbating SLE. Many other drugs are listed in Table 2. Drug-induced lupus is most frequent in older patients. Men and women are equally at risk. The most common symptoms are fever, fatigue, arthralgia, and rash.

Table 2. Medications that may cause drug-induced

lupus

Azathioprine (Imuran)

Captopril (Capoten)

Carbamazepine

Chlorpromazine HCl (Thorazine)

Conidine HCl (Catapres)

Diazepam (Diazepam, Valium)

Disopyramide (Norpace)

Gold compounds

Griseofulvin

Hydralazine HCl (Apresoline)

Ibuprofen

Interferon alfa

Isoniazid (Lanizad; Nyfazid; Trandate)

Leuprorelin acetate (Lutron)

Loratadine (Claritin)

Methylprednisolone (Sancert)

Minoxidil (Loniten, Regaine)

Primaquine (Mysoline)

Procainamide HCl (Procan, Provest)

Promethazine HCl (Avergan, Phenergan)

Prednisolone (Cuprinol, Depen)

Quinidine

Spiramycin (Azactone)

Sulfonylurea sulfate

Sulindac (Clinoril)

Sulphasalazine (Asulofidine)

Tetracycline

Thioguanine HCl (Imelal)

Timolol maleate (Betimol, Timoptic)

Tolazamide (Tolane)

Tolmetin sodium (Motrin)

Trimethadione (Tridione)

Adapted from Calligan and Williams (10).

The drugs most commonly associated with lupuslike flares include procainamide hydrochloride (Procan, Provest), hydralazine hydrochloride (Apresoline), and isoniazid (Lanizad; Nyfazid). Symptoms develop in about 30% of patients who take procainamide for more than 1 year. In patients taking hydralazine, symptoms are unlikely to occur at dosages of 200 mg/day or less.

There is no consensus on diagnostic criteria for drug-induced lupus, but it should be suspected in patients who have significant ANA titers and aminocycline antibiotics. These findings occur in more than 95% of patients with drug-induced lupus (13). Nearly all symptoms resolve after use of the drug is discontinued. Laboratory findings may persist for up to a year after symptoms resolve.

Treatment

SLE is a chronic disease that waxes and wanes. Treatment is focused on medication to control the disease and measures to prevent flares. Management is based on the degree and severity of problems. The presence of acute confusional states or fatigue should also guide

management. The measures discussed here have been shown to prolong survival and decrease morbidity.

Medications

The medications discussed here may be used alone or with other agents. Combined use may allow lower doses of each and decrease the risk of side effects.

NSAIDs treat constitutional symptoms of fatigue, musculoskeletal pain, and stiffness. Response is variable, and no one particular NSAID has proved to be better than another. Adverse effects include fever, side gastrointestinal symptoms, and high oral or intravenous doses for severe symptoms. The type of steroid used is less important than the dose. High doses should not be given for more than a month. Tapering is essential to prevent relapse and unpredictable, can usually be established.

Hydroxychloroquine was originally used to treat malaria and later found to be useful in rheumatoid arthritis. It alleviates cutaneous and musculoskeletal and constitutional symptoms. Improvement occurs over a matter of days to weeks. Patients can benefit by remaining on a prophylactic dose indefinitely. Side effects include gastrointestinal symptoms, pigment changes, and retinal damage. If acute neurologic symptoms develop, the medication should be withdrawn. Baseline ophthalmologic examination should be performed before the drug is given and at regular follow-ups.

Azathioprine is used as a second-line steroid-sparring agent to control renal manifestations and prevent proteinuria. Major side effects include bone marrow suppression. Frequent complete blood cell counts are mandatory. There may also be increased risk for certain hematopoietic cancers with use of this medication.

Cyclophosphamide is a medication of last resort to manage progressive renal disease and decrease risk of end-stage renal failure. It is used also to treat hypercoagulopathy and severe neurologic symptoms. This drug is contraindicated in pregnancy. It also increases risk for bladder damage.

Methotrexate may be used as a second-line agent for treating SLE-related arthritis and rashes. Dose (10 mg/week), an attenuated antitumor, may be useful for autoimmune thrombocytopenia, although its mechanism is unclear. Gamma globulin has some use for treating thrombocytopenia, but the response rate is high. Plasmapheresis has only transient effects, and it, too, has a high relapse rate. Research efforts are being focused on modified combination regimens to decrease side effects.

Prevention of flares

SLE symptoms can be controlled to a certain degree with preventive measures. By avoiding intense sun exposure, patients can prevent burns, which release antibodies to DNA and exacerbate rashes (1). When outside, they should wear sunscreen, a large-brimmed hat, and long-sleeved clothing. Persons with SLE should avoid outdoor occupations and photosensitizing medications.

Aggressive treatment of infections is paramount, since infection is a major cause of morbidity and mortality. Fever without a source must be thoroughly evaluated and treated. Annual inoculation with influenza vaccine is imperative. Antibiotic prophylaxis should be considered for all dental and surgical procedures. Most infections are treatable, but sulfon-based drugs should be avoided because they increase photosensitivity.

Contraception with low-dose estrogen or progestin is probably safe unless a patient has a history of thrombotic events, liver disease, or antiphospholipid antibody syndrome. Obstetric care should be managed by a perinatal specialist. Because immunosuppressants entail a risk for infertility, sperm and ova banking should be discussed.

By providing educational materials and information about support networks, physicians can help patients achieve and maintain control over their symptoms, enabling them to minimize flares and live functional, productive lives with this chronic illness.

Summary

SLE is a chronic autoimmune disease with an unpredictable history and course. It can occur in men or women at any age, but it is most prevalent in women of childbearing age. SLE displays a variety of clinical and laboratory manifestations that vary from vague constitutional symptoms to findings of end-organ dysfunction. Early recognition can lead to better treatment and preventive care, thereby avoiding the more aggressive renal, cardiovascular, and systemic manifestations. Recognition and management of lupus flares and of medication side effects can markedly reduce morbidity and mortality, allowing patients to live more functional lives.

References

1. Venables PJ. Diagnosis and treatment of systemic lupus erythematosus. *BMJ* 1993;307(6895):663-6.
2. Piskosky DS. Systemic lupus erythematosus. In: Schumacher HR, Klippel JH, Koopman WJ, eds. *Primer on the Rheumatic Diseases*. 11th ed. Arthritis Foundation, 1993:100-5.
3. Mills JA. Systemic lupus erythematosus. *N Engl J Med* 1994;330(26):181-9.
4. Von Fecht TM. Systemic lupus erythematosus: recognizing its various presentations. *Postgrad Med* 1993;97(4):79-94.
5. Esdaile JM. Progress in systemic lupus erythematosus. *Springer Semin Immunopathol* 1994;16(1-2):337-55.
6. Oster W. On the visceral complications of erythema exudative multiforme. *Am J Med Sci* 1895;110(6).
7. Hay EM, Smith ML. ABC of rheumatology: systemic lupus erythematosus and lupus-like syndromes. *BMJ* 1995;310(6969):125-6.
8. Provost TT. Skin disease in lupus. Hamline University lupus website. Available at: <http://www.hamline.edu/lupus>. Accessed July 1, 1999.
9. Boumpas DT, Austin HA 3rd, Fessler BJ, et al. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic diseases. *Ann Intern Med* 1995;122(12):940-50.
10. Calligari PE, Williams WW. Laboratory tests for rheumatic diseases: when are they useful? *Postgrad Med* 1995;97(4):65-74.
11. Lahita RG, ed. *Systemic lupus erythematosus*. 3rd ed. New York: Churchill Livingstone, 1992.
12. Lockshin MD. Pregnancy and lupus. Hamline University lupus website. Available at: <http://www.hamline.edu/lupus>. Accessed July 1, 1999.
13. Yung RL, Richardson BC. Drug-induced lupus. *Rheum Dis Clin North Am* 1994;20(1):61-86.

A brief history of lupus

The 13th century physician Rogerius coined the term "lupus" (Latin for "wolf") to describe facial lesions resembling a wolf's bite. The French Physician Cazenave later termed the reddish complexion on young female faces lupus erythematosus. In 1845, Von Hebra described the rash as having a butterfly appearance. Thirty years later, Kaposi described more of the disease's visual components (1). Near the turn of the century, Oskar Klemperer coined the term "collagen vascular disease," stressing the major mutations in the collagenous components of fibrous connective tissue associated with systemic lupus erythematosus and other autoimmune diseases.

References

1. Lahita RG, ed. *Systemic lupus erythematosus*. 2nd ed. New York:

Churchill Livingstone, 1992

2. **Oster W.** On the visceral complications of erythema exudative multiforme. *Am J Med Sci* 189:1106

INFORMATION FOR PATIENTS

Where to Find Information about SLE

Support groups exist nationwide, sponsored by the Lupus Foundation of America. A Web site lupus.home page by Hamline University, St Paul, Minnesota, provides information on all aspects of the disease, including symptoms, treatment, support groups, research, and breakthroughs in the field. The site is available at <http://www.hamline.edu/lupus>.

Thanks to Susan Vinterberg-Dent, MD, Normandi Otarz, MD, Steven Rothschild, MD, Cynthia Walkus, MD, and Richard Lord, MD, for their contribution to the writing of this article. Their insight and support are greatly appreciated.

Dr. Greenberg was chief resident, department of family medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago. He is now in private group practice in San Diego, California. Dr. Michalska is assistant professor, section of rheumatology, department of internal medicine, Rush-Presbyterian-St. Luke's Medical Center, and section chief of rheumatology, department of internal medicine, Illinois Masonic Medical Center, Chicago. Correspondence: Brent Greenberg, MD, 11157 Ice Skate Place, San Diego, CA 92126. E-mail: drburnbird@aol.com.

RETURN TO NOVEMBER 1999 TABLE OF CONTENTS

[about us](#) | [site map](#) | [home](#) | [issue index](#) | [patient notes](#) | [peers](#) | [ad services](#) |

The McGraw-Hill Companies

Copyright (C) 1999. The McGraw-Hill Companies. All Rights Reserved.
Terms of Use. [Privacy Policy.](#) [E-mail Privacy Notice.](#)

Please send technical questions related to the Web site to Alan Harske.



National
Library
of Medicine
NLM

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search <input type="text" value="PubMed"/> for <input type="button" value="Go"/>					<input type="button" value="Clear"/>				
		Limits	Preview/Index		History	Clipboard		Details	

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

<input type="button" value="Display"/>	<input type="button" value="Abstract"/>	Show: <input type="text" value="20"/>	<input type="button" value="Sort"/>	<input type="button" value="Send to"/>	<input type="button" value="Text"/>
--	---	---------------------------------------	-------------------------------------	--	-------------------------------------

1: J Clin Immunol. 1993 Sep;13(5):321-8.

Related Articles, Links

Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematoses, progressive systemic sclerosis, and mixed connective tissue disease.

Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzutto A, Hunstein W.

Medizinische Klinik und Poliklinik V, Universitat Heidelberg, Germany.

Two TNF binding proteins have been characterized as soluble fragments of TNF receptors. We measured the plasma concentrations of soluble type A (p75) and type B (p55) TNF receptors in patients with systemic lupus erythematoses (SLE), progressive systemic sclerosis (PSS), and mixed connective tissue disease (MCTD). In SLE and PSS patients plasma concentrations of both types of TNF receptors and in MCTD patients type A TNF receptors were significantly elevated compared to controls. Plasma concentrations of both soluble TNF receptors were highly correlated in SLE, PSS, and MCTD patients, indicating a possible coregulation of both TNF receptors. In contrast, soluble interleukin 2 receptor (sCD 25) plasma concentrations were not correlated and seem to be an independent parameter. The soluble forms of the TNF receptors neutralize TNF in cytotoxicity assays and are functionally active as TNF antagonists. In one patient with SLE, autoantibodies against type A TNF receptors were detected, TNF alpha, and TNF beta did not interfere with the autoantibody binding to the receptor.

PMID: 8245178 [PubMed - indexed for MEDLINE]

<input type="button" value="Display"/>	<input type="button" value="Abstract"/>	Show: <input type="text" value="20"/>	<input type="button" value="Sort"/>	<input type="button" value="Send to"/>	<input type="button" value="Text"/>
--	---	---------------------------------------	-------------------------------------	--	-------------------------------------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Search

Limits

Preview/Index

History

Clipboard

Details

About Entrez

 Show:

Text Version

 1: Int Immunol. 1993 Oct;5(10):1293-300.

Related Articles, L

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

The role of the 16/6 idiotype network in the induction and manifestations of systemic lupus erythematosus.**Waisman A, Mendlovic S, Ruiz PJ, Zinger H, Meshorer A, Mozes E.**

Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

Experimental systemic lupus erythematosus (SLE) has been induced in mice by immunization with either a human anti-DNA mAb bearing a common idiotype (Id) designated 16/6 Id (antibody 1, Ab1) or with a murine anti-16/6 Id mAb (Ab2). In the present study a murine mAb (5G12-4, Ab3) that bears the 16/6 Id and binds to DNA was produced and was found to bind rabbit anti-16/6 Id sera and murine anti-16/6 Id mAb similarly to the human mAb 16/6 Id (Ab1). Moreover, mAb 5G12-4 was shown to share cell epitopes with the human 16/6 Id mAb, since lymph node cells of mice immunized with the mAb 5G12-4 proliferated significantly to the human 16/6 mAb and vice versa. Following immunization of mice with the murine mAb bearing the 16/6 Id, antibodies to dsDNA, ssDNA, 16/6 Id, anti-16/6 Id, and to HeLa nuclear extract proteins were detected similarly to those observed previously upon immunization with Ab1 or Ab2. Six months following the immunization, the mice exhibited leukopenia, increased erythrocyte sedimentation rates, and proteinuria. Examination of the kidneys of the mice disclosed immune complex deposits, thickening of the Bowman's capsule and glomerular necrosis. These results show the importance of the 16/6 Id network in the induction and progression of SLE in mice.

PMID: 8268135 [PubMed - indexed for MEDLINE]

 Show: [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Search for [Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[Go](#)[Clear](#)[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Display](#) [Abstract](#)Show: [Sort](#)[Send to](#)[Text](#) 1: Immunol Lett. 1994 Jun;41(1):79-84.[Related Articles, L](#)

Induction of experimental systemic lupus erythematosus in mice by immunization with the F(ab')2 fragment of the human anti-DNA monoclonal antibody carrying the 16/6 idiotype.

Ruiz PJ, Zinger H, Mozes E.

Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

Induction of an experimental disease resembling murine systemic lupus erythematosus (SLE), has been achieved in mice by immunization with a human monoclonal anti-DNA antibody, bearing a common idiotype, designated 16/6 Id. In the present study we report the preparation of F(ab')2 proteolytic fragments of the human 16/6 Id mAb and the ability of the latter to induce experimental-SLE in mice. Following immunization with the F(ab' fragment, mice developed antibodies bearing the 16/6 Id, anti-16/6 Id and a variety of autoantibodies, similar to mice immunized with the whole 16/6 Id molecule. Serological manifestations of the disease such as leukopenia, proteinuria and renal damage, were developed following the immunization with the 16/6 Id F(ab')2 proteolytic fragments. These results demonstrate the pathogenic role of the F(ab')2 fragment that bears the 16/6 Id.

PMID: 7959907 [PubMed - indexed for MEDLINE]

[Display](#) [Abstract](#) Show: [Sort](#) [Send to](#) [Text](#)


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	<input type="checkbox"/> for #65					<input type="button" value="Preview"/>	<input type="button" value="Go"/>	<input type="button" value="Clear"/>
					<input checked="" type="checkbox"/> Limits	Preview/Index	History	Clipboard	Details

[About Entrez](#)

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

[Related Resources](#)

[Order Documents](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

Search	Most Recent Queries	Time	Result
#66 Search #65 Field: All Fields, Limits: Publication Date to 1996		17:10:18	85
#65 Related Articles for PubMed (Select 11299053)		17:08:44	545
#60 Search #54 AND th1 Limits: Review		17:07:17	25
#58 Search #54 Field: All Fields, Limits: Review		15:49:07	4813
#56 Search #55 Field: All Fields, Limits: Review		15:48:28	20
#55 Search systemic lupus erythematosus Field: All Fields, Limits: Clinical Trial		15:48:01	602
#54 Search systemic lupus erythematosus		15:47:35	35207
#53 Search systemic lupus erythamatosus		15:47:19	2
#51 Search j. exp. med.[jour] AND 178[volume] AND 211 [page] AND 1993[pdat] Field: Title Word		14:39:34	1
#50 Search j. immunol.[jour] AND 155[volume] AND 5280[page] AND 1995[pdat] Field: Title Word		14:38:43	1
#49 Search ettinger AND splenic		14:28:05	6
#48 Search ettinger		14:27:34	1203
#47 Search proc. natl. acac. sci. u.s.a.[jour] AND 93 [volume] AND 13107[page] AND ettinger[auth] Field: Title Word		14:27:19	0
#46 Search 93[volume] AND 13107[page] AND ettinger [auth] Field: Title Word		14:26:39	0
#45 Search proc natl acad sci usa[jour] AND 93[volume] AND 13107[page] AND ettinger[auth] Field: Title Word		14:26:33	0
#42 Search lymphotoxin beta receptor AND extracellular domain		13:38:26	5
#40 Search lymphotoxin beta receptor and structure		13:37:38	14
#39 Search LT beta receptor AND SLE		12:23:49	0
#38 Search LT beta receptor AND lupus		12:23:42	0
#37 Search LT beta receptor AND lupus Field: All Fields, Limits: Review		12:23:39	0
#34 Search lymphotoxin beta receptor Field: All Fields,		12:20:00	13

Limits: Review

#33 Related Articles for PubMed (Select 14763782)	12:19:20	<u>136</u>
#29 Search TNF beta receptor AND lymphotoxin beta receptor Field: All Fields, Limits: Review	12:14:53	<u>4</u>
#27 Search TNF beta receptor AND lymphotoxin beta receptor	12:14:22	<u>65</u>
#22 Related Articles for PubMed (Select 8245178)	12:13:51	<u>287</u>
#20 Search TNF beta receptor AND systemic erythematosus lupus	12:10:48	<u>2</u>
#14 Search prevention of systemic erythematosus lupus Limits: Review	12:03:56	<u>144</u>
#13 Search prevention of lupus Field: All Fields, Limits: Review	11:51:12	<u>229</u>
#12 Search prevention of lupus	11:51:06	<u>861</u>
#10 Search lt beta receptor and soluble Limits: Publication Date to 1996	11:21:23	<u>15</u>
#5 Search #4 Field: All Fields, Limits: Publication Date to 1996	11:20:04	<u>25</u>
#4 Related Articles for PubMed (Select 8917551)	10:20:29	<u>122</u>
#1 Search lymphotoxin beta receptor	09:54:11	<u>162</u>

[Clear History](#)[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37